Enzalutamide (Xtandi®) in Castration Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance document for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the XTANDI® (enzalutamide) PQI and explores how the medically integrated teams at Minnesota Oncology and Clearview Cancer Institute incorporate PQIs as part of their daily workflow. It will discuss how utilizing the Enzalutamide (XTANDI®) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer PQI elevates patient care at each and every fill.